The Food and Drug Administration on Monday approved wider use of a drug important to Bristol Myers Squibb’s future, clearing the medicine for people newly diagnosed with a cancer-like disease of the bone marrow.
Called Reblozyl, the drug has been available in the U.S. since 2019, when the FDA gave it the OK to treat patients with anemia due to the blood disease beta thalassemia. Bristol Myers, which inherited the drug when it acquired Celgene that year, has since focused on broadening its use, projecting more than $4 billion in global Reblozyl sales by the end of the decade.
